about
Why we object to NAOMI. Heroin maintenance in CanadaDihydrocodeine for detoxification and maintenance treatment in illicit opiate-dependent individualsUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceUpdate on Barriers to Pharmacotherapy for Opioid Use Disorders.Supervised dosing with a long-acting opioid medication in the management of opioid dependence.The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.Buprenorphine for opioid dependencePractical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner.A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville).Buprenorphine: new treatment of opioid addiction in primary care.Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.African American patients seeking treatment in the public sector: characteristics of buprenorphine vs. methadone patientsThe relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and WalesBuprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level AnalysisStudy protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.Heroin Use, HIV-Risk, and Criminal Behavior in Baltimore: Findings from Clinical Research.Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implicationsA urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.Polydrug abuse: a review of opioid and benzodiazepine combination useStates' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.Cocaine and opioid use during pregnancy: prevalence and management.Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.Buprenorphine Prescribing: To Expand or Not to ExpandInitiation of buprenorphine during incarceration and retention in treatment upon release.Italy's electronic health record system for opioid agonist treatment.Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.Illicit use of methadone and buprenorphine among adolescents and young adults in SwedenComparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002.Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.Advances in the treatment of opioid use disorders.Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.Effect of buprenorphine dose on treatment outcome.
P2860
Q24683792-0DAA260B-02EC-4F50-8865-DB6D94F7E3E1Q26471618-CDFF3C8B-55DD-4FFA-ACFC-BE14F0428F9DQ26865674-EA1CCF77-C991-4433-9B01-4D330E3AE89EQ30234408-48CA2FFD-311F-4DCC-B957-DA27F5AC8D00Q30234632-00E09C1D-F257-4477-A60C-4E327EF8A0DEQ33889324-BF8C34B1-B3A4-4B1E-9CB8-CB01F34AC140Q34119459-0278744C-CB82-47B7-A8DC-ADE99BD05950Q34228635-045BD283-59F7-4793-B851-E5477CCD47F3Q34253036-821C07BA-CA8F-46F2-8E9A-941A268FB519Q34506560-72E3EC5A-32D9-4F73-B786-2409EDD77666Q34667890-DBCE874D-EA80-4EA6-A5E5-113F4ABA52D0Q35009760-455EEA2B-8040-4393-83AC-940537338D98Q35160035-C7EB947C-F0BF-4022-AA44-6D2B2487A15DQ35653149-43CFFF49-3E1E-49F2-B451-63C63575D8B8Q35675636-85A3D202-0B53-4B77-AE99-55B68C5EB4E7Q35733030-9F783E52-BF5C-4946-8451-F599194B83FBQ35828982-1F22C8AF-889E-4029-933D-E14EB9EF00EAQ35941859-2E8D3C50-06D1-4352-B9E2-9AB3E63381BFQ35998254-D3CC8F22-5164-4EF2-8F00-BD91162D9A80Q36030969-B2C0AF13-26D8-4782-A7A0-BA6E0A708ED9Q36156096-A937E506-D10A-4890-BD83-5A7E083D55BDQ36235101-AE8B3F4F-F408-45EE-86C7-6B7609AAF744Q36266246-0F5C8567-2194-424C-B324-E33B243BD267Q36328320-AA6BC7EC-6103-4AD4-BC94-778EFDB0452CQ36474136-73CB524A-B6D5-4BD9-BBF8-530793F97DD2Q36750914-794C9597-88FB-423F-B012-56B389235711Q36855631-C40E6DC4-EB4F-4346-A4F4-DA7B5A76D38FQ36948204-2692F5BC-BED8-4467-A1E8-F0C16961FC85Q36949180-9E8F77E1-DB6D-4598-85B6-FB676762D5A3Q37067368-4DEF422A-E04D-4CB1-881A-4C317E9E4E92Q37180966-79815CAF-33A5-46CF-8BD4-EBAAFC7C3B55Q37248672-6DA65248-736B-41E8-85AB-C3DBEEABE9B3Q37346293-EAC97F56-84E1-4E0B-A484-C3E8FB7DEF0CQ37369585-4868C7E3-0033-4944-9391-C1700ED54DB9Q37405474-AF4327C3-ADAF-4527-BB65-EE5EFD601CD1Q37407584-9A32A83A-E758-4395-BC2F-7079F76DA1ABQ37470350-9C65A2CF-27CE-4205-BF34-76EF6B919C7BQ37620473-21306BEC-2862-4542-915A-9F7CA99BB54DQ37661911-289E8175-4E5E-4176-9D3C-4FCCF4E6F1F6Q37987271-ACAB3B9F-10DA-47FF-B91F-BF650380B871
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
French field experience with buprenorphine.
@en
type
label
French field experience with buprenorphine.
@en
prefLabel
French field experience with buprenorphine.
@en
P2093
P1476
French field experience with buprenorphine.
@en
P2093
Jacques Dubernet
Jean Tignol
Jean-Pierre Daulouède
Mélina Fatséas
P304
P356
10.1080/10550490490440780
P478
13 Suppl 1
P577
2004-01-01T00:00:00Z